



## Liste modèle des médicaments essentiels



### Condoms [Informations générales](#)

Section  
Barrier methods

◦ -

Indications

[Contact with health services for contraceptive management](#)



### Copper-containing intrauterine device [Informations générales](#)

Section  
Intrauterine devices

◦ -

Indications

[Contact with health services for insertion of contraceptive device](#)



### Diaphragms [Informations générales](#)

Section  
Barrier methods

◦ -

Indications

[Contact with health services for contraceptive management](#)



### Estradiol cypionate + medroxyprogesterone acetate [Informations générales](#)

Section  
Injectable hormonal contraceptives  
◦ Parenteral > General injections > IM: 5 mg + 25 mg

Indications

[Contact with health services for reasons associated with reproduction](#)



### Ethinylestradiol + etonogestrel [Informations générales](#)

Section  
Intravaginal contraceptives  
◦ Local > Vaginal > vaginal ring: 2.7 mg + 11.7 mg

Indications

[Contact with health services for contraceptive management](#)



### Ethinylestradiol + levonorgestrel [Informations générales](#)

Section

Oral hormonal contraceptives

- Oral > Solid: 50 µg + 250 µg [4]
- Oral > Solid: 30 µg + 150 µg

Indications

[Contact with health services for postcoital contraception](#) [Contact with health services for contraceptive management](#)

**Ethinylestradiol + norethisterone** [Informations générales](#)

Section

Oral hormonal contraceptives

- Oral > Solid: 35 µg + 1 mg

Indications

[Contact with health services for contraceptive management](#)

**Etonogestrel-releasing implant** [Informations générales](#)

Section

Implantable contraceptives

- Implant > Subdermal: 68 mg single rod

Indications

[Contact with health services for insertion of contraceptive device](#)

**Levonorgestrel** [Informations générales](#)

Section

Oral hormonal contraceptives

- Oral > Solid: 750 µg [2]; 1.5 mg [1]
- Oral > Solid: 30 µg

Indications

[Contact with health services for postcoital contraception](#) [Contact with health services for contraceptive management](#)

Section

Intrauterine devices

- Intrauterine system with reservoir containing 52 mg of levonorgestrel.

Indications

[Contact with health services for insertion of contraceptive device](#)

**Levonorgestrel-releasing implant** [Informations générales](#)

Section

Implantable contraceptives

- Implant > Subdermal: 75 mg per rod (two-rods)

Indications

[Contact with health services for insertion of contraceptive device](#)

**Medroxyprogesterone acetate** [Informations générales](#)

Section

Injectable hormonal contraceptives

- Parenteral > General injections > IM: 150 mg per mL in 1 mL vial
- Parenteral > General injections > SC: 104 mg per 0.65 mL in pre-filled syringe; 104 mg per 0.65 mL in single dose injection delivery system

Indications

[Contact with health services for reasons associated with reproduction](#)

**Norethisterone** [Informations générales](#)

Section

Oral hormonal contraceptives

- Oral > Solid: 350 µg

Indications

[Contact with health services for contraceptive management](#)

**Norethisterone enantate** [Informations générales](#)

Section

Injectable hormonal contraceptives

- Parenteral > General injections > IM: 200 mg per mL in 1 mL ampoule oily solution

Indications

[Contact with health services for reasons associated with reproduction](#)



**Progesterone vaginal ring [Informations générales](#)**

Section

Intravaginal contraceptives

- Local > Vaginal > vaginal ring: 2.074 g micronized progesterone

Indications

[Contact with health services for contraceptive management](#)



**Ulipristal [Informations générales](#)**

Section

Oral hormonal contraceptives

- Oral > Solid: 30 mg tablet (ulipristal acetate)

Indications

[Contact with health services for postcoital contraception](#)